Do not approve those products as routine patient-care procurement alternatives. FDA states that semaglutide sodium and acetate are different active ingredients from those in approved medicines and that it is unaware of a lawful basis for their use in compounding. FDA also warns against products falsely marketed for research while being sold for human use. (fda.gov)
Use a product-identity stop screen:
- Is the exact active ingredient disclosed?
- Is the proposed product approved or compounded?
- Is a laboratory or research designation being used to explain patient supply?
- Does the proposal identify the actual dispensing pharmacy?
- Can the supplier connect the product to legitimate sourcing and handling records?
Escalate identity mismatches immediately. A purity claim, test report or attractive price is not a substitute for an eligible patient-care route.
The appropriate procurement response to an unresolved identity issue is to stop onboarding—not to negotiate additional indemnity and proceed.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss